Stock NOVA NOVA MENTIS LIFE SCIENCE CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 03:38:53 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Nova Mentis Life Science Corp. +50.00% -25.00%
Apr. 08 Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 26 Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 11.16 6.426 23.89 6.133 14.35 2.943
Enterprise Value (EV) 1 9.163 5.579 21.75 5.914 14.09 2.935
P/E ratio -2.98 x -4.58 x -0.48 x -2.28 x -5.54 x -2.4 x
Yield - - - - - -
Capitalization / Revenue - 893,535,317 x 2,082,866,196 x - - -
EV / Revenue - 775,707,731 x 1,896,274,669 x - - -
EV / EBITDA -2.77 x -5.14 x -14 x -2.11 x -7.64 x -2.44 x
EV / FCF 224 x -20.9 x -24.8 x -5.75 x -19.3 x 15.2 x
FCF Yield 0.45% -4.78% -4.03% -17.4% -5.19% 6.6%
Price to Book 1.58 x 1.03 x 5.07 x 13.4 x 352 x -3.63 x
Nbr of stocks (in thousands) 30,998 32,132 111,138 111,503 143,523 147,169
Reference price 2 0.3600 0.2000 0.2150 0.0550 0.1000 0.0200
Announcement Date 4/30/19 6/5/20 4/30/21 5/2/22 4/25/23 4/8/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 0.007192 0.0115 - - -
EBITDA 1 -3.313 -1.086 -1.557 -2.798 -1.843 -1.202
EBIT 1 -3.322 -1.096 -1.564 -2.803 -1.847 -1.205
Operating Margin - -15,238.64% -13,633.64% - - -
Earnings before Tax (EBT) 1 -3.573 -1.398 -23.25 -2.685 -2.466 -1.224
Net income 1 -3.573 -1.398 -23.25 -2.685 -2.466 -1.224
Net margin - -19,439.47% -202,658.54% - - -
EPS 2 -0.1207 -0.0437 -0.4519 -0.0242 -0.0181 -0.008342
Free Cash Flow 1 0.0409 -0.2666 -0.8764 -1.028 -0.7308 0.1936
FCF margin - -3,707.37% -7,639.49% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/19 6/5/20 4/30/21 5/2/22 4/25/23 4/8/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2 0.85 2.14 0.22 0.27 0.01
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.04 -0.27 -0.88 -1.03 -0.73 0.19
ROE (net income / shareholders' equity) -69.3% -20.7% -424% -172% -985% 318%
ROA (Net income/ Total Assets) -38.5% -9.69% -16.7% -89.2% -196% -460%
Assets 1 9.273 14.43 138.9 3.009 1.258 0.2664
Book Value Per Share 2 0.2300 0.1900 0.0400 0 0 -0.0100
Cash Flow per Share 2 0.0100 0 0.0200 0 0 0
Capex 1 0.04 - - - - -
Capex / Sales - - - - - -
Announcement Date 4/30/19 6/5/20 4/30/21 5/2/22 4/25/23 4/8/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVA MENTIS LIFE SCIENCE CORP. Stock Nova Mentis Life Science Corp.
-25.00% 1.63M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.15% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NOVA Stock
  4. Financials Nova Mentis Life Science Corp.